Unknown

Dataset Information

0

The effects of extended pre-quit varenicline treatment on smoking behavior and short-term abstinence: a randomized clinical trial.


ABSTRACT: Preclinical research and learning theory suggest that a longer duration of varenicline treatment prior to the target quit date (TQD) would reduce smoking rates before cessation and improve abstinence outcomes. A double-blind randomized controlled trial tested this hypothesis in 60 smokers randomized to either an Extended run-in group (4 weeks of pre-TQD varenicline) or a Standard run-in group (3 weeks of placebo, 1 week of pre-TQD varenicline); all the participants received 11 weeks of post-TQD varenicline and brief counseling. During the pre-quit run-in, the reduction in smoking rates was greater in the Extended run-in group than in the Standard run-in group (42% vs. 24%, P < 0.01), and this effect was greater in women than in men (57% vs. 26%, P = 0.001). The rate of continuous abstinence during the final 4 weeks of treatment was higher among women in the Extended group compared to women in the Standard run-in group (67% vs. 35%). Although these data suggest that extension of varenicline treatment reduces smoking during the pre-quit period and may further enhance cessation rates, confirmatory evidence is needed from phase III clinical trials.

SUBMITTER: Hawk LW 

PROVIDER: S-EPMC3325094 | biostudies-literature | 2012 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

The effects of extended pre-quit varenicline treatment on smoking behavior and short-term abstinence: a randomized clinical trial.

Hawk L W LW   Ashare R L RL   Lohnes S F SF   Schlienz N J NJ   Rhodes J D JD   Tiffany S T ST   Gass J C JC   Cummings K M KM   Mahoney M C MC  

Clinical pharmacology and therapeutics 20111130 2


Preclinical research and learning theory suggest that a longer duration of varenicline treatment prior to the target quit date (TQD) would reduce smoking rates before cessation and improve abstinence outcomes. A double-blind randomized controlled trial tested this hypothesis in 60 smokers randomized to either an Extended run-in group (4 weeks of pre-TQD varenicline) or a Standard run-in group (3 weeks of placebo, 1 week of pre-TQD varenicline); all the participants received 11 weeks of post-TQD  ...[more]

Similar Datasets

| S-EPMC2615779 | biostudies-literature
| S-EPMC3281242 | biostudies-literature
| S-EPMC2815089 | biostudies-literature
| S-EPMC4430389 | biostudies-literature
| S-EPMC6545135 | biostudies-literature
| S-EPMC9354670 | biostudies-literature
| S-EPMC3547198 | biostudies-other
| S-EPMC9932870 | biostudies-literature
| S-EPMC8240875 | biostudies-literature
| S-EPMC8324080 | biostudies-literature